Surgery Websites
Transplant Surgery »  Meet the Team »  Transplant Surgeons »  Peter G. Stock, M.D., Ph.D.

Peter G. Stock, M.D., Ph.D.

Professor of Surgery
Surgical Director, Kidney and Pancreas Transplant Program
Surgical Director, Pediatric Renal Transplant Program
Co-Director, Pancreatic Islet Cell Transplant Program
Program, Director, T32 Training Program in Transplant Surgery

Contact Information

Academic Office
(415) 353-8617
peter.stock@ucsf.edu
Open Popup
  • University of Illinois, Urbana, IL, B.S., Biology, 1974-78
  • University of Illinois, Chicago, IL, M.D., Medicine, 1978-82
  • University of Minnesota, Minneapolis, MN, Ph.D., Surgery, 1985-92
  • University of Minnesota, Intern, General Surgery, 1982-83
  • University of Minnesota, Resident, General Surgery, 1983-90
  • University of California, San Francisco, Fellow, Transplant Surgery, 1990-92
  • American Board of Surgery, 1991
  • Bile Duct Injuries
  • Bile Duct Strictures
  • Cholangiocarcinoma (Bile Duct Cancer)
  • Choledochal Cyst Disease
  • Dialysis Access
  • End-Stage Kidney Disease
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Kidney and LIver Transplantation in HIV Patients
  • Kidney Transplantation
  • Liver Transplantation
  • Living Donor Kidney Transplantation
  • Living Donor Liver Transplantation
  • Pancreas Transplantation
  • Pancreatic Islet Cell Transplantation
  • Pediatric Kidney Transplantation
  • Pediatric Liver Transplantation
  • Polycystic Kidney Disease
  • Polycystic Liver Disease
  • Portal Hypertension
  • Induction of transplantation tolerance to block alloimmunity and recurrent autoimmunity following pancreatic islet transplantation
  • Safety and efficacy of solid organ transplantation in people with HIV

Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992. Dr. Stock specializes in liver, kidney and pancreas transplantation.

For many years, Dr. Stock was Chair of the Department of Surgery Research Committee. Under his  outstanding leadership. he has helped to establish UCSF Surgery as one of the top research programs for surgical residents in the U.S.

clincial investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.

Dr. Stock is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies.

  Award  
  Confired By    
  Date    
  • James IVth Fellowship Award
  • US Representative
  • 2000
  • Faculty Fellowship Award
  • American College of Surgeons
  • 1993
  • Sandoz Fellowship Award
  • American Society of Transplant Surgeons
  • 1991
  • Outstanding Surgical Resident Teaching Award
  • Department of Surgery, University of Minnesota, Minneapolis, MN
  • 1989
  • David Gaviser Award, Outstanding Surgical Research
  • University of Minnesota, Minneapolis, MN
  • 1989
  • Outstanding Research Award, Senior Medical Student
  • University of Illinois, Chicago, IL
  • 1982
  • Alpha Omega Alpha
  • University of Illinois, Chicago, IL
  • 1981
  • Magna Cum Laude, Honors in Biology with High Distinction
  • University of Illinois, Urbana, IL
  • 1978
  • Phi Beta Kappa
  • University of Illinois, Urbana, IL
  • 1978
  • Pancreatic Islet Transplantation
    The translational research in the field of pancreatic islets revolves around clinical trials of the safety and efficacy of islet transplantation in patients with Type I diabetes. The clinical trials are funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation (JDRF). These clinical trials focus on novel immunosuppressive strategies that utilize co-stimulatory blockade to prevent the immune response against pancreatic islets with a regimen that is not toxic to kidneys or beta cells.

    Related research involves improving the techniques required for isolating pancreatic islets from the pancreas, which is being conducted in a fully compliant GMP laboratory facility. The study of the alloimmune and autoimmune response following islet transplantation will be conducted to determine the efficacy of the immunosuppressive strategies. Further translational studies will include methods of expanding the source of beta cells, using direct proliferation, as well as manipulation of precursor cells localized in the adult pancreas. We are currently funded (PI) for a translational grant from California Institute of Regenerative Medicine (CIRM) to bring embryonic stem cell-derived beta cells to a clinical trial.

    Solid Organ Transplantation in People with HIV
    With the advent of highly active anti-retroviral therapy (HAART), HIV has been a chronic disease. People with HIV are no longer dying from progression of HIV to AIDS, but rather as a result of end stage live disease (viral hepatitis co-infection) and kidney disease (HIV nephropathy). Our laboratory heads up the large NIH-sponsored national multicenter trial which is studying the safety and efficacy of solid organ transplantation in people with HIV. Translational research is exploring the impact of HIV on organ function and the impact of immunosuppression on the immune response against HIV and associated copathogens.

    Data provided by UCSF Profiles, powered by CTSI
    • Filling a Void of Research (FAVOR) Training for Transplant Surgeons
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2016
      -
      Jul 2021
      Principal Investigator
    • Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2015
      -
      Jul 2020
      Principal Investigator
    • Diabetes Research Center
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2002
      -
      Mar 2020
      Co-Investigator
    • Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jan 2015
      -
      Dec 2017
      Principal Investigator
    • Solid Organ Transplantation in HIV: Multi-Site Study
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2003
      -
      Aug 2013
      Principal Investigator
    • General Clinical Research Center
      Sponsor:
      Sponsor ID:
      Funding Period:
      Dec 1974
      -
      Mar 2009
      Co-Investigator
    Data provided by UCSF Profiles, powered by CTSI
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 251
    Data provided by UCSF Profiles, powered by CTSI
    1. Boggi U, Vistoli F, Andres A, Arbogast H, Badet L, Baronti W, Bartlett ST, Benedetti E, Branchereau J, W Rd Burke G, Buron F, Caldara R, Cardillo M, Casanova D, Cipriani F, Cooper M, Cupisti A, Davide J, Drachenberg C, de Koning EJ, Ettorre GM, Fernandez Cruz L, Fridell J, Friend PJ, Furian L, Gaber O, Gruessner AC, Gruessner RW, Gunton J, Han DJ, Iacopi S, Kauffmann EF, Kaufman D, Kenmochi T, Khambalia HA, Lai Q, Langer RM, Maffi P, Marselli L, Menichetti F, Miccoli M, Mittal S, Morelon E, Napoli N, Neri F, Oberholzer J, Odorico J, Öllinger R, Oniscu G, Orlando G, Ortenzi M, Perosa M, Perrone VG, Pleass H, Redfield RR, Ricci C, Rigotti P, Robertson PR, Ross L, Rossi M, Saudek F, Scalea J, Schenker P, Secchi A, Socci C, Sousa Silva D, Squifflet JP, Stock P, Stratta R, Terrenzio C, Uva P, Watson C, White SA, Marchetti P, Kandaswamy R, Berney T. First World Consensus Conference on Pancreas Transplantation: Part II - recommendations. Am J Transplant. 2021 Jul 10. View in PubMed
    2. Stock PG, Henrich TJ, Segev DL, Werbel WA. Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid organ transplant recipients. J Clin Invest. 2021 Jun 18. View in PubMed
    3. Israni A, Wey A, Thompson B, Miller J, Casingal V, Pavlakis M, Niederhaus S, Forbes R, Wilk A, McKinney W, Kandaswamy R, Stock P, Snyder J. New Kidney and Pancreas Allocation Policy: Moving to a Circle as the First Unit of Allocation. J Am Soc Nephrol. 2021 Jun 17. View in PubMed
    4. Danovitch G, Bunnapradist S, Cohen D, Hariharan S, McKay D, Ratner L, Stegall M, Steiner R, Stock P, Vincenti F. Tests for the non-invasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. Am J Transplant. 2021 Jun 03. View in PubMed
    5. Landstra CP, Andres A, Chetboun M, Conte C, Kelly Y, Berney T, de Koning EJP, Piemonti L, Stock PG, Pattou F, Vantyghem MC, Bellin MD, Rickels MR. Examination of the Igls Criteria for Defining Functional Outcomes of ß-Cell Replacement Therapy: IPITA symposium report. J Clin Endocrinol Metab. 2021 Jun 01. View in PubMed
    6. View All Publications

     

    Site Directory
      X